Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials

Journal of Clinical Oncology

Volumn 26, Issue 22, 2008, Pages 3816-3817

  Roach III, Mack ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; LETTER; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; ADJUVANT CHEMOTHERAPY; LYMPH NODE; MALE; MORTALITY; NOTE; PATHOLOGY; PELVIS; PROSTATE TUMOR; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ANTIANDROGEN;

ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; HUMANS; LYMPH NODES; MALE; PELVIS; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 49249106624     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.9879     Document Type: Letter

References (14)

1. Nguyen PL, D'Amico AV: Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol 26:2055-2056, 2008; discussion 2056-2057
2. Roach M III, DeSilvio M, Lawton C, et al: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904-1911, 2003
3. Lawton CA, DeSilvio M, Roach M III, et al: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646-655, 2007
4. Roach M III, Hanks G, Thames H Jr, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974, 2006
5. Pommier P, Chabaud S, Lagrange JL, et al: Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25:5366-5373, 2007
6. Roach M III, DeSilvio M, Valicenti R, et al: Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66:647-653, 2006
7. Heidenreich A, Varga Z, Von Knobloch R: Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis. J Urol 167:1681-1686, 2002
8. Briganti A, Chun FK, Salonia A, et al: Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. Urology 69:147-151, 2007
9. Briganti A, Chun FK, Salonia A, et al: A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol 51:112-119, 2007; discussion 119-120
10. Briganti A, Chun FK, Salonia A, et al: Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49:1019-1026, 2006; discussion 1026-1027
11. Shariat SF, Kattan MW, Erdamar S, et al: Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. J Clin Oncol 21:1223-1231, 2003
12. Pagliarulo V, Hawes D, Brands FH, et al: Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 24:2735-2742, 2006
13. Ferrari AC, Stone NN, Kurek R, et al: Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 24:3081-3088, 2006
14. Miyake H, Hara I, Kurahashi T, et al: Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res 13:1192-1197, 2007